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Abstract. We used molecular xenomonitoring (MX, detection of filarial DNA in mosquitoes) to evaluate the impact
of mass drug administration (MDA) in sentinel locations in Egypt with high (11.5%) and low (4.1%) baseline microfi-
laria prevalence rates. Blood-fed Culex pipiens were pooled by household and tested for Wuchereria bancrofti DNA by
PCR. There was no significant relationship between the infection status of household residents and parasite DNA status
of mosquitoes from the same houses. After 5 MDA rounds, parasite DNA rates in mosquitoes in high- and low-
prevalence areas were reduced by 93.8% and 100% to 0.19% (95% CI: 0.076–0.382%) and 0% (95% CI: 0–0.045%),
respectively. These changes were consistent with decreases in microfilaria prevalence rates in these sites; they provide
insight regarding the minimal mosquito DNA rates necessary for sustained transmission of filariasis in Egypt. We
conclude that MX is a powerful tool for monitoring the impact of MDA on filariasis endemicity and transmission.
INTRODUCTION
Lymphatic filariasis (LF) is a major tropical disease with an
estimated 120 million people infected in 83 countries and
some 1,300 million at risk of acquiring the infection.1 The
World Health Assembly resolved to eliminate lymphatic fi-
lariasis as a public health problem in 1997.2 The Global Pro-
gram for Elimination of Lymphatic Filariasis (GPELF) is
based on a strategy of mass drug administration (MDA) of
4–6 annual rounds of antifilarial medications with the goal of
reducing the reservoir of blood microfilariae (MF) below the
level required for transmission by mosquitoes.3
Filariasis is focally endemic in Egypt. The mosquito vector
responsible for transmission of filariasis in Egypt is Culex
pipiens. This mosquito is widely distributed and extremely
abundant throughout the country. It is mainly anthropoph-
agic, endophagic, and endophilic.4 Prior to the initiation of
MDA in 2000, ∼137,000 people in 181 villages and towns
were infected with Wuchereria bancrofti, and 2.7 million were
at risk of acquiring the infection.5,6 Egypt was one of the first
countries that initiated a National Program for Elimination of
Lymphatic Filariasis (NPELF) based on WHO guidelines.
The program comprised 5 annual rounds of MDA with dieth-
ylcarbamazine (DEC, 6 mg/kg) and albendazole (400 mg) in
all known endemic areas in the country. MDA was distrib-
uted in September of each year from 2000 through 2004 to all
eligible people in endemic areas (excluding pregnant women
and children < 2 years of age). Reported coverage rates for
the program exceeded 90% in all years. Approximately 2.7
million people were targeted in the 5th round of MDA (100%
of the at-risk population in 2004).6
Molecular xenomonitoring (MX) employs PCR to detect
filarial DNA in wild-caught mosquitoes. Prior studies have
suggested the potential of this method for assessing the suc-
cess of filariasis elimination.5,7 Our early studies showed that
MX could be used to estimate the relative prevalence of W.
bancrofti infection in villages with high and low filariasis
prevalence rates.8 These studies used the SspI PCR assay to
test pools of indoor-resting Cx. pipiens. Although dissection
can be used to detect filarial parasites in mosquitoes, MX
becomes particularly valuable after implementation of MDA
programs, when mosquito infection rates are reduced to lev-
els that cannot be accurately assessed by dissection. MX has
the potential to be a sensitive method for detecting persistent
filarial parasites in communities. It should also provide an
indirect indication of the potential for ongoing filariasis trans-
mission.9,10
The purpose of this study was to evaluate MX as a tool for
assessing the impact of a national filariasis elimination pro-
gram in well-characterized sentinel sites. Our results show
that MX can be a practical and efficient tool for assessing the
impact of MDA in communities; it may also be useful for
determining endpoints for LF elimination programs.
METHODS
Study sites. Mosquito collections were carried out in 2 sen-
tinel study sites at approximately the same time as blood
surveys that were also conducted by our group. The study
sites included a high-prevalence area in Giza governorate
(Giz) and a low-prevalence area in Qalubiya governorate
(Qal) that had MF prevalence rates of 11.5% and 3.1% and
community MF loads of 0.534 and 0.114, respectively, just
prior to the first round of MDA in 2000.11 The Giz study area
(45 km south of Cairo) included the 2 contiguous villages of
Kafr Bahary (KB) with 1,057 houses and Kafr Qebly (KQ)
with 1,014 houses. These villages had no significant antifilarial
treatment prior to initiation of MDA. The Qal study area
included two adjacent villages (Kafr Tahoria, KT, with 208
houses and Tahoria, TH, with 852 houses) in the southeastern
Nile delta ∼35 km NE of Cairo. The Qal villages were more
typical of localities included in the Egyptian NPELF than the
Giz villages because they had low infection rates and a history
of treatment of filariasis prior to initiation of the national
program in 2000. We have reported results of prior studies of
filariasis in the Qal villages.12,13 KT was mass-treated with
DEC (6 mg/kg) in 1998; ∼20% of TH residents were screened
in the same year, and infected subjects were selectively
treated with DEC. Population estimates for KB, KQ, and TH
are between 5,000 and 6,000; ∼1,500 people live in KT. Study
sites were mapped, and houses were sequentially numbered.
Households were randomly selected for assessment of filarial
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infections using EpiInfo software, version 6.14 Approximately
10–20% of the houses in these villages were studied each year.
Blood collection and screening for W. bancrofti infec-
tion. Population surveys were conducted 2–4 months prior to
the first round of MDA and repeated each year just before
the next round of MDA for 5 consecutive years as previously
described.11 Briefly, subjects were tested for circulating fi-
larial antigen (CFA) with a rapid-format card test; persons
with positive antigen tests were tested for microfilaremia by
membrane filtration of 1 mL of night blood. Persons with
negative antigen tests were considered to be amicrofila-
remic.15
Mosquito collections. Mosquitoes were collected in 150–
200 houses per year in each of the 2 study areas, with new
houses sampled each year. Collections were carried out from
May to August for 6 successive years (from 2000 to 2005), 1–4
months pre-MDA, and 8–11 months after each of 5 annual
rounds of MDA. Individual houses were visited on a weekly
basis for 1 month (4–5 visits per house). Sampling was con-
ducted in each village approximately the same time each year.
Trained field technicians aspirated resting mosquitoes on
walls and beneath furniture in bedrooms from 10 PM to 1 AM
(about 10 minutes/house). Female Cx. pipiens were counted
and classified according to their abdominal appearance as
blood-fed, gravid, or empty (neither blood-fed nor gravid)
and transferred into labeled 1.5-mL Eppendorf tubes that
were stored at −70°C for later detection of W. bancrofti DNA.
Only blood-fed and gravid mosquitoes were retained for PCR
analysis; empty mosquitoes were discarded. Mosquitoes from
houses with > 25 fed or gravid females were divided into
equal pools for PCR testing.
Detection of W. bancrofti DNA in Cx. pipiens. We used a
standard PCR protocol for detecting W. bancrofti DNA in
mosquitoes.9 This method uses NV-1 and NV-2 primers to
amplify the SspI DNA repeat sequence.16 The test detects 1
pg of genomic W. bancrofti DNA, which is < 1% of the DNA
content of a single microfilaria. The 188-bp amplified product
was detected by agarose gel electrophoresis. Each PCR run
included 2 types of negative control (DNA from unfed Cx.
pipiens and a no-template control). Three types of positive
controls were also tested in each PCR run: a dissected mos-
quito that contained 1 or more filarial worms, DNA from
non-blood-fed mosquitoes that was spiked with purified W.
bancrofti DNA, and purified SspI-DNA PCR product.
Estimation of filarial DNA rates in resting mosqui-
toes. Parasite DNA rates in mosquitoes (maximum likelihood
with 95% CI) were estimated by PoolScreen 2.0 software as
previously described.17 We also analyzed PCR results in
terms of the percent of positive pools and percent of houses
with positive mosquitoes. The distribution of filarial infec-
tions within each study site was assessed by scoring houses as
being in the “core” or “periphery” of the village. Peripheral
houses face vacant lots or agricultural land on at least one
side, whereas core houses are surrounded by other houses.
Statistical analysis. Data were analyzed with SPSS 11.0 soft-
ware (SPSS, Inc., Chicago, IL). Proportions were compared
by 2 or Fisher exact tests. The Mann–Whitney U test was
used to compare group means for nonparametric data.
Ethical clearance. This study was reviewed and approved
by institutional review boards at Ain Shams University and at
Washington University School of Medicine. The Egyptian
Ministry of Health and Population also approved the study.
RESULTS
General description of study areas. There were 1,060
houses in the Qal study area. Figure 1 shows that the 130
houses surveyed before the first round of MDA in TH were
distributed throughout the village. The major mosquito
breeding sites identified in TH were 2 cesspools in the north-
ern and NE edges of the village. The major mosquito breed-
ing sites in KT were 2 abandoned wells near the edge of the
village in the northeast sector. The Giz study area consisted of
2,071 houses. The main mosquito breeding site in Giz is a
polluted drainage canal that runs along the east side of the
study area.
Mosquito collection and the influence of the number of
mosquitoes per pool on detection of W. bancrofti. Cx. pipiens
comprised > 99% of indoor-resting mosquitoes collected in
both study areas. Other species included Ochlerotatus caspius,
Anopheles tenebrosus, and Anopheles pharoensis. In the
months just prior to the first round of MDA, 6,571 female Cx.
pipiens were collected from 223 houses in Giz in 946 house-
nights (7.0 ± 5.6 [SD] mosquitoes per house-night). Of these,
∼50.0% were blood-fed or gravid (14.7 ± 8.7 per house col-
lected in 4 or 5 nights). In Qal, 2,671 Cx. pipiens females were
captured from 179 houses in 728 house-nights (3.7 ± 3.0 per
house-night), and 44.9% of the females were blood-fed or
gravid (6.6 ± 4.4 per house collected in 4 or 5 nights). Thus
mosquito densities were higher in Giz than in Qal (P < 0.001).
The number of mosquitoes collected per house-night tended
to increase slightly over the course of the study (data not
shown). Therefore, decreased infection rates in humans and
mosquitoes after MDA did not result from changes in mos-
quito densities in the study areas.
Figure 2 shows the relationship between the number of
mosquitoes tested per house and the percent of houses with
mosquitoes that contained W. bancrofti DNA for each year of
the study. The pre-MDA data show that the percent of posi-
tive pools increased with pool size in both study areas. The
proportion of positive pools decreased after MDA for both
large and small mosquito pools. These differences were sig-
nificant for pool sizes of 10 or more mosquitoes in both areas
(P  0.01).We consider pools with < 10 mosquitoes to be
suboptimal for MX assessment of filarial DNA in mosquitoes
by household.
Figure 3 shows frequency distributions for the number of
blood-fed or gravid mosquitoes collected in houses in the 2
study areas, pre-MDA. Despite 4–5 visits per house, < 10 fe-
males were recovered in many of the houses in both
study areas (74.3% of 179 houses studied pre-MDA in Qal,
and 35.0% of 223 houses in Giz). This is a significant limita-
tion for using the percent of positive houses to follow parasite
DNA rates in mosquitoes in endemic areas. In contrast,
PoolScreen 2.0 takes pool size into account for estimation of
parasite DNA rates in mosquitoes. However, analysis of PCR
results by household should provide information on the gen-
eral location of mosquitoes with parasite DNA in a study
area.
Impact of MDA on parasite DNA in household mosquito
collections (poolwise analysis). Five rounds of MDA signifi-
cantly reduced the frequency of positive mosquito pools in
both study areas (P  0.001) for pools with  5 females
(Figure 4) and also for houses with pools of  10 females
(data not shown). Parasite DNA rates in mosquitoes de-
FARID AND OTHERS594
creased more quickly in Qal (with the low baseline MF preva-
lence rate) than in Giz.
Impact of MDA on filarial DNA rates in mosquitoes (pool-
wise and PoolScreen analyses). Table 1 shows parasite DNA
rates in mosquitoes in the 2 study areas before and after
MDA. This analysis includes all mosquito pools. Baseline in-
fection rates were similar in the 2 areas prior to MDA. Para-
site DNA rates in mosquitoes and the percentage of positive
pools declined more rapidly after MDA in Qal than in Giz.
Five rounds of MDA decreased the parasite DNA rate in Giz
mosquitoes by 93.8%, from 3.066% to 0.190%, and the per-
centage of mosquito pools with parasite DNA decreased by
90.2%. The MF prevalence rate in humans in Giz decreased
from 11.5% to 1.2% by membrane filter during this time
(89.6% decrease); the post-MDA MF rate by 50-L thick
smear was 0.3%.
Five rounds of MDA decreased the parasite DNA rate in
mosquitoes, percent positive mosquito pools, and MF preva-
lence by 100% in Qal. Indeed, only a few positive mosquito
pools or MF carriers were detected in Qal after the second
round of MDA.
Effect of location in the village on mosquito and human
infection rates. Prior studies in Egypt have suggested that fi-
lariasis infection rates are higher in peripheral houses (houses
that face vacant or agricultural land) than in core houses
(houses that are surrounded by other houses).18 Therefore,
we compared human infection rates and parasite DNA rates
in mosquitoes in peripheral and core houses pre-MDA in Giz
FIGURE 1. Map of Tahoria village in the Qal study area, showing households where mosquitoes were collected for PCR testing prior to the
first round of mass drug administration (MDA):, houses with mosquitoes positive for filarial DNA by PCR;, houses with mosquitoes negative
for filarial DNA by PCR; housing blocks are shown as squares; dashed lines represent irrigation and drainage canals.
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and Qal (Table 2). Human infection and parasite DNA rates
in mosquitoes were essentially the same in core and periph-
eral houses in Giz. Human infection rates were higher in
peripheral houses in the Qal study area, although only the
filarial antigen test difference was statistically significant. The
parasite DNA rate in Qal mosquitoes was higher in core
houses, but this difference was not statistically significant.
Thus, household location (core versus periphery) was not a
major risk factor for filariasis in these study areas.
Relationship between filarial DNA in mosquitoes and hu-
man filariasis in households. Households with one or more
MF carriers before MDA did not have significantly higher
filarial DNA rates in mosquitoes than houses without MF
carriers (Table 3). Mosquitoes with parasite DNA were some-
times detected in households where none of the tested resi-
dents had MF, whereas no PCR-positive mosquitoes were
detected in some houses with MF-positive residents. After
MDA-5, MF-positive people were detected in 5 houses in Giz,
but no filarial DNA was detected in mosquitoes collected in
these houses. No MF carriers and no DNA-positive mosqui-
toes were detected in Qal houses after MDA-5.
DISCUSSION
This study was conducted in 2 areas in Egypt in the context
of its NPELF. The Qal study area had a low filariasis preva-
lence rate before the initiation of MDA in September 2000.
This area was fairly typical of filariasis-endemic villages in
Egypt just prior to the NPELF. In contrast, Giz had very high
filariasis endemicity (for Egypt) pre-MDA. This was probably
due to a lack of prior systematic treatment in the area, high
mosquito densities, and perhaps other uncharacterized local
conditions favorable for transmission.
We have previously shown that MX is useful for comparing
filariasis endemicity levels in different areas.8 Several prior
studies have used PoolScreen to estimate filarial DNA rates
FIGURE 4. Impact of mass drug administration on the percent of
houses with Wuchereria bancrofti DNA in Culex pipiens in the Giz
(gray bars) and Qal (black bars) study areas. Data are shown for
households with mosquito pool sizes  5; error bars show 95% con-
fidence limits.
FIGURE 2. Effect of mosquito sample size on the percentage of
houses with Wuchereria bancrofti DNA in Culex pipiens in the Giz
(A) and Qal (B) study areas. Histograms show results obtained be-
fore the first round of mass drug administration (MDA) and after
each round of MDA.
FIGURE 3. Frequency distributions for the number of houses with
different numbers of gravid or blood-fed Culex pipiens captured be-
fore treatment in the Giz (A) and Qal (B) study areas.
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in culicines. For example, Goodman and co-workers, using
20-L thick smears,10 found a filarial DNA rate in mosqui-
toes of 7.2% in an area in Haiti where 11.0% of the people
had microfilaremia. A study from Egypt reported a filarial
DNA rate in mosquitoes of 8.1% by MX with PoolScreen
when the MF prevalence rate by 50-L smear was 9.5%.17
Lower parasite DNA rates in mosquitoes in the current study
are generally consistent with these published results, given
that the MF rates in the present study are based on membrane
filtration of venous blood rather than thick smear. We were
surprised to see equivalent pre-MDA parasite DNA rates in
mosquitoes in Giz and Qal because of the difference in MF
rates in these areas. Limitation (enhanced ability of Culex
mosquitoes to ingest MF at low blood MF levels) may have
contributed to this finding.19,20 We doubt that infection rates
in Qal were inflated by contamination in the laboratory, be-
cause we included negative controls in each PCR run. It is
possible that mosquitoes were older (with more prior feedings
on average) in Qal than in Giz. A prior study by our group
showed that differences in rates of daily mosquito survival
and survival to infectivity might explain local differences in
filariasis endemicity.21 Because PCR can detect parasite
DNA taken up at any time during a mosquito’s life, age could
certainly affect parasite DNA rates in mosquitoes.22 We did
not assess mosquito parity in this study. In any case, we be-
lieve that comparison of parasite DNA rates in selected areas
over time (as in this study) is more useful than comparisons
between villages at a single point in time.
Prior studies have reported clustering of mosquitoes and
human filarial infections at the edges of villages where larval
breeding sites are concentrated and where residents are ex-
posed to more mosquito bites.18,23,24 Although the main mos-
quito breeding sites were in peripheral locations in both of
our study sites, we did not observe significantly higher para-
site DNA rates in mosquitoes, higher human infection rates,
or higher mosquito abundance (data not shown) in peripheral
houses in this study.
The Egyptian NPELF achieved high MDA coverage rates,
and this had a dramatic impact on MF rates in humans.11 Our
study shows that MDA also had a dramatic impact on parasite
DNA in mosquitoes whether this is expressed as the percent
of mosquitoes with parasite DNA using PoolScreen or as the
percent of houses with parasite DNA in mosquitoes. MDA
had a more rapid impact on both measures of parasite DNA
in mosquitoes in Qal, where MF prevalence rates and counts
had already been decreased by treatment prior to initiation of
MDA in 2000.
Researchers in Papua New Guinea and Haiti have reported
significant declines in W. bancrofti infection rates in mosqui-
toes by dissection after MDA.10,25 However, this is the first
study that has demonstrated dramatic decreases and clear-
ance of filarial DNA in mosquitoes after MDA using MX.
Very large numbers of mosquitoes have to be tested to detect
low residual filarial infection rates in mosquitoes after MDA
and to show the absence of filarial infections with any degree
of certainty. MX is superior to dissection for this purpose
TABLE 2





No. ICT card, % Positive MF filter, % Positive No. of pools % Infected (95% CI)
Giz Periphery 517 18.4 10.6 126 3.12 (2.20–4.28)
Core 322 18.6 12.1 83 3.76 (2.43–5.50)
P 0.998 0.585
Qal Periphery 310 18.7 3.5 64 3.48 (1.79–5.94)
Core 193 8.3 2.1 46 6.54 (3.39–11.11)
P 0.005 0.356
* “Periphery” refers to houses that faced vacant land on at least one side. “Core” houses were surrounded by other houses on all sides.
TABLE 1
Impact of 5 annual rounds of mass drug administration (MDA-0 to MDA-5) of single-dose DEC/Alb on Wuchereria bancrofti DNA rates in Culex
pipiens collected in the Giz and Qal study areas
Mosquitoes
Study area MDA round No. tested No. of pools Mosq./pool ± SD % Infected pools
PoolScreen mosquito infection estimates
% 95% CI
Giz MDA-0 3,270 248 13.2 ± 5.8 33.5 3.07 2.38–3.88
MDA-1 1,446 155 9.3 ± 5.4 15.5 1.76 1.08–2.68
MDA-2 2,364 155 15.3 ± 5.1 24.5 1.84 1.25–2.58
MDA-3 2,543 174 14.6 ± 5.0 9.8 0.70 0.38–1.14
MDA-4 3,970 252 15.8 ± 4.5 7.1 0.47 0.27–0.77
MDA-5 4,273 245 17.4 ± 4.3 3.3 0.19 0.08–0.38
Qal MDA-0 1,197 179 6.7 ± 4.3 24.6 4.37 3.07–5.99
MDA-1 1,832 153 12.0 ± 5.2 3.3 0.28 0.08–0.66
MDA-2 1,374 136 10.1 ± 6.4 0.7 0.07 0.00–0.38
MDA-3 2,110 151 14.0 ± 5.0 0.0 0.00 0.00–0.09
MDA-4 3,730 220 17.0 ± 3.9 1.4 0.08 0.02–0.24
MDA-5 4,258 237 18.0 ± 3.7 0.0 0.00 0.00–0.05
MOLECULAR XENOMONITORING OF LYMPHATIC FILARIASIS 597
because of its high sensitivity and its high-throughput capa-
bility. For example, we detected a residual parasite DNA rate
of 0.19% (CI: 0.076–0.38) in Giz mosquitoes after MDA-5
with 4,273 mosquitoes in 245 pools. Confidence limits for
parasite DNA rates in mosquitoes become smaller with larger
mosquito samples. However, as with dissection, there are
practical limits to the number of mosquitoes that can be cap-
tured and tested by PCR.
At this stage of the GPELF, when a number of countries
have completed 5 or more rounds of MDA, there is height-
ened interest in endpoints or targets that program managers
can use to decide when to stop MDA.26 A recent paper sug-
gested a post-MDA target of 0.5% MF for culicine-
transmitted filariasis.27 Based on our experiences with MX in
Egypt, we believe it is reasonable for MDA programs to aim
for residual parasite DNA rates in mosquitoes with an upper
confidence limit of 0.25%. This is a conservative target that
might be lower than necessary. In practical terms, this target
is met if no more than 3 of 200 pools of 15 fed or gravid
mosquitoes are positive by PCR. This proposed target applies
to Culex mosquitoes. Other targets will be needed for areas
where filariasis is transmitted by Anopheles or Aedes mosqui-
toes. The parasite DNA rate in Giz mosquitoes was just over
our proposed target after MDA-5 (0.38%), when the MF rate
in Giz was 1.2% by filter and 0.3% by 50-L blood smear.
Parasite DNA rates met this target in Qal after MDA rounds
3–5, when MF rates in the population were well under 0.5%
by filter. The target might also have been achieved in Qal
after MDA-2 (when the residual MF rate was 0.6% by filter)
if more mosquitoes had been tested. The small number of
mosquitoes and pools tested that year limited the power of
MX to show that the target had been reached. Of course, low
residual rates of parasite DNA in mosquitoes do not neces-
sarily mean that filariasis transmission is ongoing in an area.
Prior studies by our group showed that mosquitoes fed on
people with very low MF levels sometimes ingested MF but
rarely produced infective larvae.28 These mosquitoes would
have been scored as positive by PCR. More data are needed
on relationships between MF rates and other parameters after
MDA to firm up targets for MDA programs.
More work is needed to develop better guidelines for mos-
quito sampling for monitoring by dissection or MX. A WHO
workshop report recommended collection of at least 1,000
mosquitoes (10–50 mosquitoes per house, with 100–250
households) per sentinel site prior to MDA.5 More mosqui-
toes are needed to detect parasites by MX or dissection when
infection rates are reduced by MDA.5,29,30 Our results con-
firm that large mosquito samples are critical for detecting W.
bancrofti infection during late stages of a MDA program.
Pool infection rates were higher for larger pools. This empha-
sizes the advantage of following PoolScreen estimates of
DNA rates in mosquitoes over the simpler parameter “per-
cent of positive pools.”
We were able to obtain sufficient samples of resting mos-
quitoes for MX studies in this research project. However, the
mosquito capture method we used is labor intensive and in-
trusive to village residents; our experienced field teams col-
lected only 3.8 ± 3.5 (median 3) blood-fed or gravid mosqui-
toes per house-night. This method is probably not practical
for large-scale evaluation of national elimination programs.
Gravid traps, which capture blood fed culicine mosquitoes in
the act of oviposition, might be more practical for conducting
MX on a large scale. Although filarial DNA rates in gravid
trap mosquitoes tend to be somewhat lower than those in
resting mosquitoes (Gad AM and others, unpublished data),
we have found that gravid traps are much more efficient than
aspiration of resting mosquitoes for collecting large numbers
of Cx. pipiens for MX.
Improvements are also needed on technical aspects of MX
for it to be practical for use in large-scale filariasis elimination
programs. DNA isolation and PCR methods used in this
study are labor-intensive and inefficient. New methods for
isolation of DNA from mosquitoes and real-time PCR (with
better sensitivity and throughput capacity relative to conven-
tional PCR) promise to greatly improve our capacity to test
large numbers of mosquitoes.31 Work is also ongoing to fur-
ther improve the statistical analysis and interpretation of MX
data.
We found no significant relationship between filarial infec-
tions in humans and filarial DNA in mosquitoes in individual
households. Filarial DNA was sometimes detected in mosqui-
toes collected in houses with no MF carriers and sometimes
not detected in houses with MF carriers. Thus, MX was not
useful for identification of households with MF carriers in this
study. Such households may be more efficiently detected by
pooling night blood samples by household for PCR testing in
areas where filarial DNA is detected in mosquitoes. Complex
blood feeding behavior may have contributed to the discrep-
ancy between MF and MX test results. MF carriers may have
been away from their houses when mosquitoes were blood
feeding, or they may have not served as a blood source for
collected mosquitoes. Positive mosquitoes may have taken
blood from microfilaremic visitors in or near houses where
they were captured, or they may have ingested MF in prior
feedings. They also may have fed on microfilaremic house-
hold members who did not have blood collected for MF test-
ing. Endophagic mosquitoes like Cx. pipiens rest indoors to
release excess fluid from ingested blood for 6–8 hours after
feeding, and they fly away once this process is completed.32,33
However, studies in Egypt and India have shown that blood-
TABLE 3
Relationship between rates of filarial DNA in Culex pipiens and human infections in Giz and Qal households before mass drug administration
Mosquitoes
Study area Household status* No. of houses tested No. tested No. of pools Mosq./pool ± SD
% Pools positive
for filarial DNA
PoolScreen mosquito infection estimates
% 95% CI
Giz MF-negative 127 1,797 138 13.0 ± 5.8 32.6 3.0 2.14–4.16
MF-positive 61 948 70 13.5 ± 5.9 41.4 3.9 2.49–5.72
Qal MF-negative 112 772 112 6.9 ± 4.5 27.7 4.9 3.22–7.15
MF-positive 14 84 14 6.0 ± 3.8 21.4 4.3 0.83–12.03
* “MF-negative” means that no microfilaria carriers were identified in the household sample; “MF-positive” means that at least 1 person tested in the house had microfilaremia.
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fed mosquitoes sometimes move between houses.8,34,35
Therefore, the lack of concordance between the presence of
MF carriers and DNA-positive mosquitoes in the same
houses is not too surprising.
In conclusion, this study has provided interesting data on
the use of MX in the context of filariasis elimination pro-
grams. Our data show that MX is a powerful tool for assessing
the impact of MDA, and we have suggested a MX-based
target that might be used with other targets such as MF rate
for filariasis elimination programs in areas where filariasis is
transmitted by Culex mosquitoes. We have also highlighted
limitations of current methods and suggested changes that
may make MX more practical for large-scale use.
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